Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease

Q Lin, B Fang, H Huang, F Yu, X Chai, Y Zhang… - Blood Cancer …, 2015 - nature.com
A 16-year-old male patient was admitted to our hospital in March 2012 with chief complaints
of systemic lymphadenopathy for> 4 years with significant enlargement in the bilateral …

[引用][C] Successful treatment of relapsed idiopathic multicentric Castleman disease–idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case …

Y Gao, M Duan, J Li, L Zhang - British Journal of Haematology, 2024 - Wiley Online Library
To the Editor, Idiopathic multicentric Castleman disease (iMCD) represents a group of poorly
understood lymphoproliferative disorders with limited treatment options. 1 Despite …

Tuberculous lymphadenitis mimicking Castleman disease-like histological features

M Ide, T Yokoyama, T Ogino - International Journal of Hematology, 2019 - Springer
Multicentric Castleman disease (MCD) is an indolent lymphoproliferative disorder of
unknown etiology. Due to the absence of specific histological features in Castleman …

[HTML][HTML] Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy

E Bayram, UA Pehlivan, D Fajgenbaum… - American journal of …, 2023 - ncbi.nlm.nih.gov
A 20-year-old Turkish male presented with fatigue, abdominal pain, weight loss, and night
sweats. Physical examination revealed hepatosplenomegaly and axillary lymphadenopathy; …

Multifocal Castleman disease in pediatrics: case report

M Baserga, M Rosin, M Schoen… - Journal of Pediatric …, 2005 - journals.lww.com
Multicentric Castleman disease is a rare lymphoproliferative disorder of unknown cause. It is
especially rare in children. The authors describe a 4-year-old girl that presented with …

[PDF][PDF] Interferon-α as first-line therapy for treatment of multicentric Castleman's disease

E Andres, F Maloisel - Annals of Oncology, 2000 - researchgate.net
Castleman's disease is an atypical lymphoproliferative disorder, associated with
dysregulated overproduction of interleukin-6 (IL-6) and with systemic manifestations [1] …

Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib

AA Khan, F Siraj, M Bhargava, S Aggarwal - Case Reports, 2012 - casereports.bmj.com
Castleman9s disease represents an atypical lymphoproliferative disorder which is non-
clonal but can turn malignant in the form of lymphoma, Kaposi9s sarcoma or plasma cell …

Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease

TH Beckham, JC Yang, KW Chau, A Noy… - … Lymphoma Myeloma and …, 2020 - Elsevier
Background Castleman disease (CD) is a rare polyclonal lymphoproliferative disorder of
unclear etiology. Standard therapy for unicentric CD is surgical resection. Radiotherapy can …

Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: responding to rituximab

A Iskandar, A Hwang… - Journal of Oncology …, 2019 - journals.sagepub.com
Castleman disease is a rare B-cell lymphoproliferative disorder characterized by lymph
node enlargement with or without constitutional signs. Herein, we describe a unique patient …

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report

E Lang, B Sande, S Brodkin… - Therapeutic Advances …, 2022 - journals.sagepub.com
Human herpes virus-8 (HHV8)-negative, idiopathic multicentric Castleman disease (iMCD)
is a rare lymphoproliferative disorder sustained by pro-inflammatory cytokines, including …